Atlas Trials

Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)

Clinical trial NCT02342353 · TERMINATED

Trial details

NCT number
NCT02342353
Sponsor
Washington University School of Medicine
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Non-Small Cell Lung CancerNonsmall Cell Lung CancerCarcinoma, Non-Small-Cell Lung
Start date
2015-05-18
Primary completion
2018-02-06
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.